$TROX

Tronox Reports Second Quarter 2026 Financial Results

Tronox Holdings plc (NYSE:TROX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue rose to $868 million, up 19% year over year. It posted a GAAP net loss of $171 million, or $1.07 per diluted share, and adjusted net loss of $82 million. Adjusted EBITDA was $73 million. The company expects full-year 2026 positive free cash flow and Q3 adjusted EBITDA of $95-$115 million.

Original reporting
Published Aug 5, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tronox Reports Second Quarter 2026 Financial Results — source image
Decision brief

The 30-second read

$TROXBullishMed
01

Why it matters

Traders can update models around Q3 profitability and cash generation expectations using the provided Adjusted EBITDA range ($95-$115M) and directional assumptions for TiO2/zircon volumes and pricing.

02

Market read

The release combines a Q2 datapoint set (revenue, adjusted EBITDA, free cash flow) with forward-looking Q3 guidance that can drive near-term repricing.

03

What to watch

The guidance is explicitly subject to macro, supply chain, and inflation-related challenges, and the article notes limited GAAP reconciliation detail for non-GAAP metrics, which can increase uncertainty around the durability of cash generation.

Relevance 8/10Novelty 8/10Timing: after-hours guidance and Q2 print released Aug. 5, 2026

Background

Tronox, an integrated TiO2 pigment and zircon producer, released Q2 2026 financial results and provided Q3 2026 outlook on volumes, pricing, and Adjusted EBITDA.

Company-level read

Ticker impact

$TROXBullishMedium confidence
Context

Tronox reported Q2 2026 results and guided Q3 Adjusted EBITDA to $95-$115 million, plus TiO2 and zircon pricing/volume expectations.

Expected impact

Likely modest positive bias if the market focuses on the Q3 EBITDA range and sequential pricing improvement, but leverage and net loss may cap upside.

Evidence & confidence

The article provides fresh, company-specific guidance (Q3 EBITDA range, TiO2/zircon volume and pricing direction) and a cash-flow datapoint (Q2 free cash flow $60M). However, it does not include consensus comparisons or a full reconciliation, limiting conviction on magnitude versus expectations.

Market effects

TiO2 and zircon pricing guidance (mid-single-digit TiO2, mid-to-high single-digit zircon) can influence sentiment across pigment and zircon supply-chain names.

Middle East geopolitical uncertainty is cited as an industry uncertainty factor, which could affect broader industrial materials risk appetite.

Trade defense measures and structural industry shifts are referenced, reinforcing a potentially supportive global demand and pricing backdrop for TiO2/zircon.

Counterpoint

Despite positive sequential pricing and Q3 EBITDA guidance, the company still posted a large GAAP net loss and high net leverage (11.4x), so the market may discount the outlook if macro or exchange-rate headwinds worsen.

Key entities

  • Tronox Holdings plc

    Integrated TiO2 pigment and zircon manufacturer reporting Q2 2026 results and Q3 guidance.

  • John Romano

    CEO who discussed volume performance, pricing actions, cost program progress, and working capital initiatives.

Related articles

$TROXMed

Tronox Holdings plc (TROX): Results of Operations and Financial Condition

Tronox Holdings plc (TROX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20079573_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Tronox Reports Second Quarter 2026 Financial Results STAMFORD, Conn., August 5, 2026/PRNewswire/ — Tronox Holdings plc (NYSE:TROX) (“Tronox” or the “Company”), the world’s leading integrated manufacturer of titanium dioxid

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.

$CPTMedAI 8/10

Camden Property Trust (CPT) Q2 2026 Earnings Call Transcript

Camden Property Trust (CPT) discussed its Q2 2026 earnings call, focusing on exiting its California multifamily portfolio. According to management, it sold the 19-year-old California portfolio for $1.625 billion, with trailing 12-month FFO and AFFO yields of 5.6% and 5.2%. Camden repurchased $694 million of shares and closed $645 million of acquisitions plus $195 million of awarded acquisitions, reaffirming $6.75/share FFO guidance.